Peptide and small molecule agonists of epha and their uses in disease
US-2017165322-A1 · Jun 15, 2017 · US
Peptide and small molecule agonists of EphA and their uses
US11944624B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11944624-B2 |
| Application number | US-201816628990-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 3, 2018 |
| Priority date | Jul 6, 2017 |
| Publication date | Apr 2, 2024 |
| Grant date | Apr 2, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X—Z (I).
First claim
Opening claim text (preview).
Having described the invention, the following is claimed: 1. A pharmaceutical composition comprising: a compound having the formula: wherein R 2 is selected from H, an alkoxy or a C 1-6 alkyl group, Z is selected from the group consisting of R 7 is selected from H, an alkoxy or a C 1-6 alkyl group, and n 1 is an integer from 1-20, and pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1 , the compound selected from the group consisting of: pharmaceutically acceptable salts thereof. 3. The pharmaceutical composition of claim 2 , the compound having the formula: or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition of claim 2 , the compound having the formula: or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 1 , the compound selected from the group consisting of: pharmaceutically acceptable salts thereof. 6. The pharmaceutical composition of claim 1 , the compound selected from the group consisting of: pharmaceutically acceptable salts thereof.
Assignees
Inventors
Classifications
- A61K31/517Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07D239/95Primary
with hetero atoms directly attached in positions 2 and 4 · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11944624B2 cover?
- A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X—Z (I).
- Who is the assignee on this patent?
- Univ Case Western Reserve
- What technology area does this patent fall under?
- Primary CPC classification A61K31/517. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).